RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.
Fiche publication
Date publication
mai 2018
Journal
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MERLIN Jean-Louis
Tous les auteurs :
Lièvre A, Merlin JL, Sabourin JC, Artru P, Tong S, Libert L, Audhuy F, Gicquel C, Moureau-Zabotto L, Ossendza RA, Laurent-Puig P, Ducreux M
Lien Pubmed
Résumé
RAS (NRAS + KRAS) mutation testing is required in addition to simple KRAS testing prior to initiating anti-epidermal-growth-factor-receptor (EGFR) antibodies (MAb) as in metastatic colorectal cancer (mCRC).
Mots clés
Colorectal cancer, Genotyping, KRAS mutations, RAS
Référence
Dig Liver Dis. 2018 May;50(5):507-512